Semaglutide / Cyanocobalamin Injection — GLP-1 + Vitamin B12

Semaglutide:

• Pancreatic: Glucose-dependent stimulation of insulin secretion; suppression of glucagon release — reduces post-meal glucose spikes without causing hypoglycemia in normal-glucose states.
• Gastric: Slows gastric emptying, prolonging satiety and blunting post-meal glucose elevation.
• Hypothalamic Appetite Regulation: Acts on GLP-1 receptors in the hypothalamic arcuate nucleus and reward centers to reduce appetite, increase satiety, and decrease caloric intake — independent of calorie restriction willpower.
• Cardiovascular: Clinical trials (SUSTAIN-6, SELECT) demonstrate cardiovascular risk reduction in type 2 diabetes patients and in adults with overweight/obesity.

Cyanocobalamin (Vitamin B12):

• Cofactor for methionine synthase (homocysteine methylation) and methylmalonyl-CoA mutase (odd-chain fatty acid catabolism)
• Essential for myelin synthesis and neurological integrity
• Required for RBC maturation (deficiency causes megaloblastic anemia)
• Supports cellular energy metabolism and DNA synthesis

Primary Indications:

• Chronic weight management in adults with BMI ≥30, or ≥27 with a weight-related comorbidity (hypertension, type 2 diabetes, dyslipidemia, OSA)
• Type 2 diabetes mellitus — glycemic control as an adjunct to diet and exercise
• Cardiovascular risk reduction in adults with type 2 diabetes and established cardiovascular disease

Patient Selection Criteria:

• BMI ≥27 with at least one weight-related comorbidity, or BMI ≥30 regardless of comorbidities
• Failed lifestyle intervention alone
• No personal or family history of medullary thyroid carcinoma (MTC) or MEN2
• No prior pancreatitis or significant GI motility disorders

Compounded Semaglutide is not the same as the FDA-approved Ozempic® or Wegovy®. Compounded versions require a patient-specific prescription. FDA has noted the availability of commercially manufactured semaglutide and guidance on compounding may evolve.

Contraindications:

• Personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN2) — black box warning
• Known hypersensitivity to semaglutide or any formulation component
• Pregnancy — potential fetal harm; stop 2 months before planned pregnancy
• Breastfeeding — not recommended; safety not established
• Active or history of pancreatitis — use with extreme caution

Warnings & Precautions:

• Thyroid C-Cell Tumors: Rodent studies show C-cell tumor risk at therapeutic semaglutide doses. Human relevance uncertain but MTC contraindication is absolute.
• Pancreatitis: Discontinue if pancreatitis is suspected; do not reinitiate if confirmed.
• Gallbladder Disease: Increased risk of cholelithiasis and cholecystitis; monitor for biliary symptoms with chronic use.
• Hypoglycemia: Risk increased when used with insulin or insulin secretagogues; dose adjustments of concomitant agents may be needed.
• Tachycardia: Modest increase in resting heart rate (2–3 bpm); monitor in patients with arrhythmias.
• Severe GI Disease: Avoid in patients with gastroparesis or severe inflammatory bowel disease.

Common Side Effects:

• Nausea (most common), vomiting, diarrhea, constipation, abdominal pain — primarily during dose escalation
• Injection site reactions (minimal with SQ technique)
• Fatigue, dizziness, headache (generally transient)

Drug Interactions:

• Insulin / sulfonylureas — increased hypoglycemia risk; reduce doses of secretagogues as directed
• Oral medications with narrow therapeutic windows — slowed gastric emptying may alter oral drug absorption kinetics; monitor closely

• Refrigerate at 2°C to 8°C (36°F to 46°F) prior to first use
• After first use: may be stored at room temperature up to 25°C (77°F) for the duration of use (per prescriber instruction and BUD label)
• Do not freeze; discard if frozen
• Protect from light; store in original carton
• Discard after the beyond-use date on the label
• Dispose of used needles/syringes in a proper sharps container
• Keep out of reach of children and pets
• The medicine should be fine for 5 days from the shipping date at temperatures up to 105 degrees Fahrenheit.

Is compounded semaglutide the same as Ozempic® or Wegovy®?

No. Compounded Semaglutide is a patient-specific preparation made in a 503A-licensed compounding pharmacy pursuant to a valid prescription. It is not the FDA-approved product. The compounded version may contain additional components such as cyanocobalamin (B12) and uses the semaglutide base (as a salt). Patients should discuss this distinction with their prescriber.

Why is Vitamin B12 included?

Significant appetite reduction during semaglutide therapy can lead to reduced dietary B12 intake. The addition of cyanocobalamin supports neurological function, energy metabolism, and red blood cell production, helping to offset potential B12 depletion during treatment.

How much weight can I expect to lose?

Clinical trials with branded semaglutide at 2.4 mg/week show average weight reductions of 10–15% of body weight over 68 weeks when combined with a reduced-calorie diet and exercise. Individual results depend on dose, adherence, diet, and physical activity.

Will I regain weight if I stop?

Yes — significant weight regain typically occurs after discontinuation, as seen in the STEP 4 trial. Semaglutide addresses physiological appetite signaling; management of the underlying metabolic condition continues to require ongoing treatment or major lifestyle modification.

What if I experience nausea?

Nausea is most common during the first few weeks of each dose escalation. Eat small, bland meals, avoid fatty foods, stay hydrated, and avoid lying down immediately after eating. Your prescriber may slow the dose escalation if nausea is significant. Anti-nausea medications may be prescribed if needed.

Do I still need to diet and exercise?

Yes. Semaglutide is most effective when used alongside a structured reduced-calorie diet and regular physical activity. It is not a standalone solution and should be part of a comprehensive weight management program.

Can I take it if I have type 2 diabetes?

Yes, semaglutide is used for both weight management and glycemic control in type 2 diabetes. Your prescriber will adjust your current diabetes medications (especially insulin or sulfonylureas) to prevent hypoglycemia.